Stockscreener 앱 받기
42.00
1.06%
-0.45
전일 마감가:
$42.45
열려 있는:
$42.15
하루 거래량:
2.85M
Relative Volume:
1.89
시가총액:
$3.01B
수익:
-
순이익/손실:
$-368.95M
주가수익비율:
-7.574
EPS:
-5.5453
순현금흐름:
$-293.81M
1주 성능:
+1.94%
1개월 성능:
+32.83%
6개월 성능:
-13.78%
1년 성능:
+72.48%
1일 변동 폭
$38.86
$42.15
1주일 범위
$38.86
$44.60
52주 변동 폭
$19.07
$56.05
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
42.00 | 3.01B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | 개시 | BofA Securities | Buy |
| 2025-08-04 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | 재개 | H.C. Wainwright | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch - Yahoo Finance
New Vera Therapeutics employees receive $40.13 stock options in inducement plan - Stock Titan
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)? - Yahoo Finance
Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced? - Sahm
(VERA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval - Yahoo Finance
Rx Rundown: Vertex Pharmaceuticals, Real Chemistry, Vera Therapeutics and more - Medical Marketing and Media
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Form 4 Vera Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million - Investing.com
Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported - Stock Titan
Vera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade) - Seeking Alpha
Vera Therapeutics names Nancy Boman as chief regulatory officer By Investing.com - Investing.com India
Vera Therapeutics, Inc. Files Form 8-K with SEC: Key Company and Stock Information for July 2026 - Minichart
Vera Therapeutics Announces New Chief Regulatory Officer - TipRanks
Vera Therapeutics names Nancy Boman as chief regulatory officer - Investing.com
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner - The Manila Times
Executive shakeup at Vera Therapeutics (VERA) as new Chief Regulatory Officer named - Stock Titan
Vera Therapeutics Announces Appointment of Nancy Boman as - GlobeNewswire
Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval - MedCity News
Vera Therapeutics (VERA) Q4 2025 earnings summary - Quartr
Vera Therapeutics (VERA) Q1 2026 earnings summary - Quartr
Vera Therapeutics (VERA) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
Vera Therapeutics (VERA) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says - Moomoo
Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval By Investing.com - Investing.com South Africa
Vera Therapeutics stock price target raised to $125 by H.C. Wainwright on FDA approval By Investing.com - Investing.com South Africa
Guggenheim raises Vera Therapeutics stock price target on FDA approval By Investing.com - Investing.com India
FDA grants accelerated approval to Vera Therapeutics' Trutakna - qz.com
US FDA approves Vera's kidney disease drug - Reuters
Vera Therapeutics (VERA) Proxy filing Summary - Quartr
Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval - Investing.com
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $47 to $125 - Moomoo
Vera Therapeutics stock price target raised to $125 by H.C. Wainwright on FDA approval - Investing.com South Africa
Vera Therapeutics wins FDA accelerated approval for Trutakna - The Pharma Letter
TRUTAKNA’s Dual-Pathway FDA Nod Could Be A Game Changer For Vera Therapeutics (VERA) - Sahm
Vera Therapeutics (VERA) FDA announcement Summary - Quartr
Vera Therapeutics (NASDAQ:VERA) stock up; Trutakna approval shifts attention to Q3 kidney data - TechStock²
Vera Therapeutics wins first FDA approval with kidney disease drug - The Business Journals
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Why Is Vera Therapeutics Stock Gaining Tuesday? - Benzinga
VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale - StocksToTrade
Vera Therapeutics gains FDA nod for TRUTAKNA launch - TipRanks
Vera Therapeutics secures FDA approval for TRUTAKNA - grafa.com
Vera gains after FDA nod for kidney disease therapy - Seeking Alpha
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy - The Manila Times
FDA grants accelerated approval to Vera Therapeutics (NASDAQ: VERA) drug TRUTAKNA - Stock Titan
FDA approves Vera Therapeutics kidney disease treatment - STAT
Vera Therapeutics Receives FDA Accelerated Approval for - GlobeNewswire
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Jun 23 '26 |
Sale |
37.93 |
18,500 |
701,769 |
198,244 |
2.64%
자본화:
|
볼륨(24시간):